ADMA Biologics, Inc. Stock News

The top five biotech stocks today have several commonalities. Among them are strong ratings.

ADMA Biologics has demonstrated significant revenue growth, margin expansion, and profitability, leading to a 1,314% increase in share price since 2021. The company's Q1 performance showed a 40% YoY revenue increase, strong demand for ASCENIV, and improved gross profit margins. ADMA's financial health is robust, with $171M in cash and receivables, reduced debt costs, and a new $500M share repur...

ADMA Biologics, Inc. (NASDAQ:ADMA ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - Founder, Director, President and Chief Executive Officer Brad Tade - Chief Financial Officer and Treasurer Conference Call Participants Anthony Petrone - Mizuho Group Rick Miller - Cantor Fitz...

1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue ( 1 ) of $118.6 Million), a 40% YoY Increase

While major market indexes like the S&P 500 have struggled to gain traction in 2025 and remain in the red YTD, certain pockets of the market are showing impressive strength. Several medical and biotechnology sector mid-cap stocks have stood out for their resilience and outperformance.

RAMSEY, N.J. and BOCA RATON, Fla.

Approval Supports Revenue Growth and Margin Expansion Opportunity, and Substantially Increases Peak Production Output Capacity

Reiterates Strategic Advantage Through Fully U.S.-Based Manufacturing Operations, Commercialization and End-Market Sales, and Vertically Integrated U.S.-Based Supply Chain Reiterates Strategic Advantage Through Fully U.S.-Based Manufacturing Operations, Commercialization and End-Market Sales, and Vertically Integrated U.S.-Based Supply Chain